1. Home
  2. SKT vs ACAD Comparison

SKT vs ACAD Comparison

Compare SKT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKT

Tanger Inc.

HOLD

Current Price

$40.22

Market Cap

4.5B

Sector

Real Estate

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.13

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKT
ACAD
Founded
1981
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
SKT
ACAD
Price
$40.22
$21.13
Analyst Decision
Hold
Buy
Analyst Count
6
22
Target Price
$37.17
$30.55
AVG Volume (30 Days)
676.4K
1.2M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
3.18%
N/A
EPS Growth
N/A
69.12
EPS
0.24
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$0.37
$18.80
Revenue Next Year
$3.90
$11.70
P/E Ratio
$165.88
$1,069.50
Revenue Growth
N/A
40.45
52 Week Low
$29.24
$19.69
52 Week High
$40.47
$28.35

Technical Indicators

Market Signals
Indicator
SKT
ACAD
Relative Strength Index (RSI) 73.87 45.41
Support Level $35.18 $21.04
Resistance Level N/A $22.03
Average True Range (ATR) 0.79 0.58
MACD 0.48 0.01
Stochastic Oscillator 92.14 28.67

Price Performance

Historical Comparison
SKT
ACAD

About SKT Tanger Inc.

Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: